In 2019, its inaugural year, the PRIORITY program seeks to support innovative research that could identify patients with Duchenne muscular dystrophy (DMD) at an early age. Specifically, PTC aims to facilitate research that will help to:

  • Improve DMD screening methods and increase the frequency of screening for DMD
  • Improve rates of DMD screening in infants and facilitate earlier diagnosis of this progressive, muscle-wasting disease
  • Improve understanding among clinicians on how different screening techniques can support an early diagnosis of DMD
  • Reduce the average age at which patients with DMD are diagnosed (currently 4–4.5 years)

Funding will be awarded to research programs that demonstrate the most innovation, vision and empowerment for the DMD community and recipients will be identified through a competitive application process. Research proposals will be reviewed by an external Review Committee from around the world who will not see identifying information included in the proposal except the country of origin. The 2019 Review Committee members were selected for their significant interest and expertise in neuromuscular diseases and previous experience with funding initiatives.


How to apply

  • Applications for 2019 funding will be accepted from Thursday, January 31 to Sunday, March 31.
  • Applications must include a completed funding application form including the research proposal and clear contact information.
  • Submission guidelines, a list of eligible countries, and the funding application form can be downloaded [here].
  • Each institution is only permitted to submit one application per year.
  • Completed applications can be submitted via email to PRIORITY_submissions@ptcbio.com. Please include the completed funding application form as an attachment.
  • Within five business days, you will receive confirmation that your application has been accepted for review. If you do not receive confirmation, please contact  PRIORITY@pharmagenesis.com.
  • Applicants will be notified of the outcome of their submission in late April 2019.
  • A written agreement, defining the basic conditions for the project financing, will be developed between PTC Therapeutics and the funding recipients.
  • Review Committee members will not be eligible to submit an application for this program

For 2019, the program welcomes proposals that fulfil one or more of the following categories:

Collaborative proposals involve two or more research groups work together towards a common goal.

Innovative proposals reflect a unique and novel approach that will benefit the neuromuscular disease community, either in a specific geographic location or the overall global community.

Sustaining proposals are designed for a worthy project that is already underway and requires funding to continue.

For each of the categories above, proposals will be reviewed based upon the financial request listed in the funding application form. An overall fund of US $500,000 will be available, to be divided between successful applicants. Eligible individuals and teams who meet the criteria are invited to apply for funding support that are up to US $200,000.

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue